ADMA

ADMA Biologics, Inc. [ADMA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ADMA Stock Summary

Top 10 Correlated ETFs

ADMA


Top 10 Correlated Stocks

ADMA


In the News

10:31 27 Sep 2023 ADMA

Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

02:31 27 Sep 2023 ADMA

Why Shares of ADMA Biologics Are Climbing Thursday

ADMA grew revenue and trimmed its losses compared to the same quarter a year ago. The company increased revenue guidance for 2023, 2024, and 2025.

07:00 27 Sep 2023 ADMA

ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023

RAMSEY, N.J. and BOCA RATON, Fla.

10:15 27 Sep 2023 ADMA

ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?

On ADMA Biologics' (ADMA) Q2 earnings call, investors will likely focus on the sales performance of its immune deficiency disorder drugs.

08:37 27 Sep 2023 ADMA

New Strong Buy Stocks for July 7th

ADMA, APOG, KIND, JBL and OII have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2023.

11:43 27 Sep 2023 ADMA

GSK Announces Extension of FDA Review for Rare Blood Therapy

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.

02:15 27 Sep 2023 ADMA

ADMA Biologics: An Emerging Growth Play

Today, we take a deeper look at ADMA Biologics, Inc., whose stock has doubled over the past year thanks to robust sales growth. The company continues to expand its plasma collection network, is delivering impressive growth and is pursuing margin enhancing initiatives. An investment analysis follows in the paragraphs below.

10:50 27 Sep 2023 ADMA

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

Here is how Adma Biologics (ADMA) and Novartis (NVS) have performed compared to their sector so far this year.

11:25 27 Sep 2023 ADMA

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

Here is how Adma Biologics (ADMA) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.

06:59 27 Sep 2023 ADMA

Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates

Adma Biologics (ADMA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago.

ADMA Financial details

Company Rating
Neutral
Market Cap
789.42M
Income
-65.55M
Revenue
208.11M
Book val./share
0.66
Cash/share
0.28
Dividend
-
Dividend %
-
Employees
617
Optionable
No
Shortable
Yes
Earnings
07 Nov 2023
P/E
-12.06
Forward P/E
-
PEG
2.5
P/S
3.84
P/B
5.39
P/C
12.71
P/FCF
-15.54
Quick Ratio
2.37
Current Ratio
6.35
Debt / Equity
1.03
LT Debt / Equity
1.03
-
-
EPS (TTM)
-0.32
EPS next Y
-
EPS next Q
-0.2
EPS this Y
-29.51%
EPS next Y
-
EPS next 5Y
124.61%
EPS last 5Y
-21.58%
Revenue last 5Y
55.43%
Revenue Q/Q
5.64%
EPS Q/Q
-50.26%
-
-
-
-
SMA20
-
SMA50
-
SMA100
33.33%
Inst Own
74.53%
Inst Trans
1%
ROA
-19%
ROE
-48%
ROC
-0.06%
Gross Margin
27%
Oper. Margin
-8%
Profit Margin
-31%
Payout
-
Shs Outstand
224.91M
Shs Float
209.02M
-
-
-
-
Target Price
5.25
52W Range
2.24-4.65
52W High
-11%
52W Low
+78%
RSI
39
Rel Volume
0.28
Avg Volume
2.17M
Volume
603.88K
Perf Week
-2.47%
Perf Month
-19.82%
Perf Quarter
5.64%
Perf Half Y
7.23%
-
-
-
-
Beta
0.806016
-
-
Volatility
0.03%, 0.19%
Prev Close
0.28%
Price
3.56
Change
1.42%

ADMA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0.380.540.490.580.78
Net income per share
-1.45-1.05-1.02-0.61-0.43
Operating cash flow per share
-1.39-1.4-1.18-0.81-0.3
Free cash flow per share
-1.43-1.47-1.33-0.9-0.37
Cash per share
0.50.490.650.370.44
Book value per share
0.440.481.021.010.77
Tangible book value per share
0.270.360.960.970.75
Share holders equity per share
0.440.481.021.010.77
Interest debt per share
1.11.721.270.830.88
Market cap
108M217.39M167.98M196.81M767.75M
Enterprise value
129.47M275.37M209.73M248.64M835.68M
P/E ratio
-1.64-3.81-1.92-2.33-9.01
Price to sales ratio
6.367.413.982.434.98
POCF ratio
-1.72-2.85-1.65-1.75-12.9
PFCF ratio
-1.67-2.72-1.46-1.56-10.46
P/B Ratio
5.468.31.91.395.05
PTB ratio
5.468.31.91.395.05
EV to sales
7.629.384.973.075.42
Enterprise value over EBITDA
-2.28-6.88-3.27-4.3-21.3
EV to operating cash flow
-2.07-3.61-2.06-2.21-14.04
EV to free cash flow
-2-3.44-1.83-1.98-11.38
Earnings yield
-0.61-0.26-0.52-0.43-0.11
Free cash flow yield
-0.6-0.37-0.68-0.64-0.1
Debt to equity
2.243.231.110.731.02
Debt to assets
0.50.670.470.370.44
Net debt to EBITDA
-0.38-1.45-0.65-0.9-1.73
Current ratio
4.636.127.716.876.89
Interest coverage
-10.92-4.61-5.42-4.47-2.04
Income quality
0.951.581.351.570.9
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.320000
Research and developement to revenue
0.230.080.140.050.02
Intangibles to total assets
0.080.050.030.020.01
Capex to operating cash flow
0.030.050.120.120.23
Capex to revenue
-0.12-0.13-0.3-0.17-0.09
Capex to depreciation
-0.61-1.17-3.23-2.46-1.96
Stock based compensation to revenue
0.130.090.070.040.03
Graham number
3.783.374.843.712.73
ROIC
-1.02-0.44-0.39-0.27-0.16
Return on tangible assets
-0.81-0.47-0.43-0.31-0.25
Graham Net
-0.8-0.83-0.150-0.08
Working capital
34.9M71.79M133.79M178.35M231.13M
Tangible asset value
12.24M19.5M82.28M135.91M147.43M
Net current asset value
-24.58M-15.08M34.32M73.65M73.91M
Invested capital
2.243.231.110.731.02
Average receivables
2.64M2.43M8.35M20.91M22.04M
Average payables
5.91M7.54M10.12M11.75M12.83M
Average inventory
15.62M35.84M67.3M103.13M144M
Days sales outstanding
29.9243.15114.44128.8636.73
Days payables outstanding
51.0484.7765.9556.8740.64
Days of inventory on hand
161.04490.29485.56570.7501.6
Receivables turnover
12.28.463.192.839.94
Payables turnover
7.154.315.536.428.98
Inventory turnover
2.270.740.750.640.73
ROE
-3.33-2.18-0.99-0.6-0.56
Capex per share
-0.05-0.07-0.15-0.1-0.07

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
0.170.210.250.260.27
Net income per share
-0.09-0.1-0.13-0.06-0.03
Operating cash flow per share
-0.07-0.07-0.04-0.07-0.03
Free cash flow per share
-0.09-0.08-0.05-0.08-0.03
Cash per share
0.270.180.430.310.28
Book value per share
0.580.510.750.660.66
Tangible book value per share
0.560.490.730.640.64
Share holders equity per share
0.580.510.750.660.66
Interest debt per share
0.790.810.790.730.71
Market cap
388.78M477.21M786.98M734.56M821.7M
Enterprise value
487.63M595.03M854.9M821.08M910.7M
P/E ratio
-5.3-5.82-7.59-14.39-32.25
Price to sales ratio
11.4711.6115.7512.9113.67
POCF ratio
-30.3-35.92-106.65-49.89-135.62
PFCF ratio
-23.18-28.64-70.72-44.07-118.55
P/B Ratio
3.44.755.185.045.6
PTB ratio
3.44.755.185.045.6
EV to sales
14.3814.4817.114.4315.15
Enterprise value over EBITDA
-65.3-79.79-135.36-1.66K449.51
EV to operating cash flow
-38-44.79-115.85-55.77-150.31
EV to free cash flow
-29.08-35.7-76.83-49.26-131.39
Earnings yield
-0.05-0.04-0.03-0.02-0.01
Free cash flow yield
-0.04-0.03-0.01-0.02-0.01
Debt to equity
1.321.521.021.071.03
Debt to assets
0.510.510.440.460.44
Net debt to EBITDA
-13.24-15.8-10.75-174.9743.93
Current ratio
7.945.046.897.196.35
Interest coverage
-2.01-1.67-1.06-0.13-0.08
Income quality
0.930.890.62.170.95
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.030.030.020.020.02
Intangibles to total assets
0.020.020.010.010.01
Capex to operating cash flow
0.310.250.510.130.14
Capex to revenue
-0.12-0.08-0.07-0.03-0.01
Capex to depreciation
-2.29-1.82-1.94-0.96-0.42
Stock based compensation to revenue
0.040.030.020.020.03
Graham number
1.111.11.470.920.65
ROIC
-0.04-0.05-0.0400
Return on tangible assets
-0.06-0.07-0.08-0.04-0.02
Graham Net
-0.22-0.35-0.08-0.11-0.11
Working capital
194.7M179.65M231.13M227.36M224.29M
Tangible asset value
109.5M95.66M147.43M141.29M142.58M
Net current asset value
40.24M23.92M73.91M68.95M69.98M
Invested capital
1.321.521.021.071.03
Average receivables
22.26M19.89M18.2M21.01M31.63M
Average payables
12.75M18.29M19.21M13.09M12.52M
Average inventory
142.61M154.49M163.1M163.63M162.88M
Days sales outstanding
50.1345.7827.9241.9354.98
Days payables outstanding
39.2272.1533.2528.8625.04
Days of inventory on hand
503.02466.45410.43365.31335.23
Receivables turnover
1.81.973.222.151.64
Payables turnover
2.31.252.713.123.59
Inventory turnover
0.180.190.220.250.27
ROE
-0.16-0.2-0.17-0.09-0.04
Capex per share
-0.02-0.02-0.02-0.010

ADMA Frequently Asked Questions

What is ADMA Biologics, Inc. stock symbol ?

ADMA Biologics, Inc. is a US stock , located in Ramsey of Nj and trading under the symbol ADMA

Is ADMA Biologics, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $4.83. The lowest prediction is $4 and the highest is $6

What is ADMA stock prediction ?

What is ADMA Biologics, Inc. stock quote today ?

ADMA Biologics, Inc. stock price is $3.56 today.

Is ADMA Biologics, Inc. stock public?

Yes, ADMA Biologics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks